Prevalence of Human Papillomavirus Infection in Women in Portugal: the CLEOPATRE Portugal Study
Overview
Oncology
Affiliations
Objective: Human papillomavirus (HPV) is responsible for a range of diseases, including cervical cancer. The primary objectives of the CLEOPATRE Portugal study were to estimate the overall and age-stratified prevalence of cervical HPV infection and to assess HPV prevalence and type-specific distribution by cytological results among women aged 18 to 64 years, who reside in mainland Portugal.
Materials And Methods: This cross-sectional population-based study recruited women aged 18 to 64 years, according to an age-stratified sampling strategy, who attended gynecology/obstetrics or sexually transmitted disease clinics across the 5 regional health administrations in mainland Portugal between 2008 and 2009. Liquid-based cytology samples were collected and analyzed centrally for HPV genotyping (clinical array HPV 2 assay) and cytology. Prevalence estimates were adjusted for age using 2007 Portuguese census data.
Results: A total of 2326 women were included in the study. The overall prevalence of HPV infection in the study was 19.4% (95% confidence interval, 17.8%-21.0%), with the highest prevalence in women aged 18 to 24 years. High-risk HPV types were detected in 76.5% of infections, of which 36.6% involved multiple types. The commonest high-risk type was HPV-16. At least 1 of the HPV types 6/11/16/18 was detected in 32.6% of infections. The HPV prevalence in normal cytology samples was 16.5%. There was a statistically significant association between high-risk infection and cytological abnormalities (P < 0.001).
Conclusions: This is the first population-based study to quantify and describe cervical HPV infection in mainland Portugal. This study provides baseline data for future assessment of the impact of HPV vaccination programs.
High-Risk HPV Detection in Paraffin-Embedded Tissue from Cervical Lesions.
Almeida M, Caeiro V, Costa D, Silva L, Sousa C, Pestana P Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338364 PMC: 11434968. DOI: 10.3390/ph17091201.
Luz Pereira A, Chaves Beca D, Buchner Sousa M, Vaz Pinto M, Bento D, Leal I Cureus. 2024; 16(3):e57023.
PMID: 38545422 PMC: 10966656. DOI: 10.7759/cureus.57023.
Associated factors to human papillomavirus vaccine adhesion in adult women: a cross-sectional study.
Sarabando R, Vilela-Gomes A, Reis I, Pacheco A, Nogueira-Silva C Porto Biomed J. 2023; 8(1):e181.
PMID: 37213246 PMC: 10194588. DOI: 10.1097/j.pbj.0000000000000181.
Bobadilla M, Villagra V, Ortiz V, Deluca G, de Paula V PLoS One. 2023; 18(4):e0283542.
PMID: 37023094 PMC: 10079089. DOI: 10.1371/journal.pone.0283542.
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D, Ribeiro I, Penedones A, Mendes D, Alves C, Batel-Marques F BMC Womens Health. 2023; 23(1):96.
PMID: 36894908 PMC: 9999620. DOI: 10.1186/s12905-023-02219-0.